The Percutaneous shunting in Lower Urinary Tract Obstruction (PLUTO) study and randomised controlled trial: evaluation of the effectiveness, cost-effectiveness and acceptability of percutaneous vesicoamniotic shunting for lower urinary tract obstruction

RK Morris,1,2 GL Malin,1 E Quinlan-Jones,1 LJ Middleton,3 L Diwakar,4 K Hemming,5 D Burke,5 J Daniels,3 E Denny,6 P Barton,4 TE Roberts,4 KS Khan,1 JJ Deeks3,5 and MD Kilby1,2* on behalf of the PLUTO Collaborative Group

1School of Clinical and Experimental Medicine, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK
2Fetal Medicine Centre, Birmingham Women’s Hospital NHS Foundation Trust, Edgbaston, Birmingham, UK
3Birmingham Clinical Trials Unit, University of Birmingham, Birmingham, UK
4Health Economics Unit, School of Health and Population Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK
5Public Health, Epidemiology and Biostatistics, School of Health and Population Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK
6Centre for Health and Social Care Research, Faculty of Health, Birmingham City University, Edgbaston, Birmingham, UK

*Corresponding author
Declared competing interests of authors: Dr Hemming carried out paid peer-review work for statistical review, as statistical editor, of papers submitted to BJOG and she is the parent of a baby born with a lower urinary tract obstruction. Before the start of this project Dr Daniels was a co-investigator on a project grant from Wellbeing of Women to initiate the PLUTO trial. Professor Denny has received royalties for three academic textbooks on health sociology. Professor Khan provides expert reports in medical negligence cases for which a fee is paid by instructing solicitors. In addition, Professor Khan has received grants from public bodies and pharmaceutical companies in the UK and EU. Money was paid to Professor Khan and his institution from Ferring Pharmaceuticals and various universities and societies and he has received honoraria for speaking at meetings. Professor Khan has also received royalties for his books from publishers Hodder Arnold and Huber and payment for advice on medial research, and he and his institution have received sponsorship from Ferring Pharmaceuticals, Leo-Pharma, Alere, Ethicon, Hologic, Viforpharma and Preglem/Quintiles for organising educational meetings. Before the start of this project Professor Khan was a co-investigator on a project grant from Wellbeing of Women to initiate the PLUTO trial. Before the start of this project Professor Kilby received a project grant from Wellbeing of Women to initiate the PLUTO trial. He also received a $750 honorarium for air travel to a debate in the USA on the role of fetal vesicoamniotic shunting at the Society of Maternal and Fetal Medicine, San Francisco, CA, USA in February 2013. He will be the Visiting Professor at the University of Delft and Leiden in June 2013. This will be to lead a joint meeting between fetal medicine subspecialists and paediatric urologists on congenital bladder neck obstructions. He will be paid travelling expenses and subsistence only. Professor Kilby also provides expert witness statements for medical negligence claims for which a fee is paid by instructing solicitors. All other authors declared no competing interests.

Published December 2013
DOI: 10.3310/hta17590

Scientific summary

The PLUTO study and randomised controlled trial
Health Technology Assessment 2013; Vol. 17: No. 59
DOI: 10.3310/hta17590
NIHR Journals Library  www.journalslibrary.nihr.ac.uk
Scientific summary

Background

Congenital lower urinary tract obstruction (LUTO) may be identified using prenatal ultrasound and is associated with a high perinatal mortality and high infant and childhood morbidity because of the prevalence of chronic renal impairment. Ultrasound-directed, in utero, vesicoamniotic shunting (VAS) bypasses the congenital urethral obstruction to potentially improve fetal outcome.

Objectives

The Percutaneous shunting in Lower Urinary Tract Obstruction (PLUTO) study aimed to determine the effectiveness, cost-effectiveness and patient acceptability of VAS for fetal LUTO.

The primary objective of the study was to determine whether intrauterine VAS to treat LUTO improves perinatal and neonatal mortality (survival to 28 days) and renal function compared with conservative, non-interventional care.

Secondary objectives included cost-effectiveness of VAS compared with conservative management; effects of VAS on short-term morbidity; survival and development of chronic renal failure at 1 year of age; identifying prognostic markers of outcome; determining clinicians’ prior beliefs about the effectiveness of VAS; and assessing influences on women’s decision-making with respect to opting for termination of pregnancy (TOP), randomisation and the acceptability of the intervention. We also studied the epidemiology of this condition using population-based methodology.

Methods

Randomised controlled trial and registry

A multicentre, international randomised controlled trial (RCT) was undertaken, supplemented by a register of pregnancies with LUTO not recruited to the RCT because of patient or clinician preference and an anonymous register of TOPs associated with this congenital anomaly. Expert opinions on the relative benefits of VAS and conventional treatment were elicited from fetal medicine specialists, paediatric nephrologists and paediatric urologists for use in a Bayesian analysis. The planned sample size of the trial was 150 but recruitment was abandoned after 31 women were randomised.

Setting

Fetal medicine departments across England, Scotland, Ireland and the Netherlands.

Population

Pregnant women with a singleton, male fetus with isolated LUTO.

Intervention

Randomisation was to either insertion of a VAS or conservative management. Insertion of the VAS was under continuous ultrasound examination of the fetus. During pregnancy both groups were followed with regular ultrasound scans.
**Outcome measures**
The primary outcome measure was survival to 28 days with secondary outcome measures being 1-year survival and renal function at 28 days and 12 months measured using serum creatinine, renal ultrasound and evidence of renal impairment. Prospective follow-up was arranged at 28 days and 12 months by paediatric nephrologists/urologists to assess these secondary outcomes.

**Analysis**
An intention-to-treat (ITT) approach was followed, supplemented by analysis comparing groups according to the intervention received (as treated). Intrauterine deaths and TOPs were included, classed as a death in the first instance, although a sensitivity analysis was performed excluding non-treatment-related TOP.

The relationship between gestational age at diagnosis, liquor volume at diagnosis, maternal age and survival to 28 days was assessed in a logistic regression analysis using combined data from randomised and registry patients.

**Bayesian analysis for the randomised controlled trial**
Expert opinions on the relative benefits of VAS and conventional treatment were elicited from fetal medicine specialists, paediatric nephrologists and paediatric urologists. Bayesian models were used to estimate the effectiveness of VAS at 28 days (a logistic model) and survival to 1 year of age (a Cox regression model). Bayesian prior distributions utilising evidence elicited from experts in the field and enthusiastic, sceptical and uninformative priors were used. The same priors were incorporated into the Cox proportional hazards regression analysis, excluding the elicited priors as these were obtained for perinatal survival only.

**Economic analysis for the randomised controlled trial**
A model-based economic evaluation, based on a decision tree utilising data inputs on resource use and outcomes from the RCT, assessed the cost-effectiveness of VAS compared with standard conservative management. Unit costs from routine sources were applied to resource use.

The model adopted a time horizon of 1 year. All analyses took the perspective of the NHS and results are presented in terms of cost per additional survivor at 28 days, cost per survivor at 1 year and cost of disability-free survival. We conducted deterministic and probabilistic sensitivity analyses to explore data uncertainty and the robustness of the results.

**Patient acceptability study**
A patient acceptability study using a phenomenological approach was used to explore the ways in which women make sense of their experiences and to elicit their motivations for participation in the RCT. A series of semistructured interviews were undertaken with a purposive sample of RCT and registry patients to elicit the lived experience of women.

**Epidemiological study**
A retrospective study identified a population of fetuses affected by LUTO delivering between 1995 and 2007 and recorded in the West Midlands Congenital Anomaly Register (WMCAR). Cases were selected using International Classification of Diseases, 10th Edition (ICD-10) codes and keyword terms and diagnoses were validated using additional data sets from regional fetal medicine, perinatal pathology and paediatric services. Outcome measures were incidence, prenatal diagnosis rates and mortality.

**Results**

*Results of the randomised controlled trial and registry study*
A total of 31 women from seven centres were randomised between October 2006 and October 2010. Of those randomised to VAS, 3/16 (19%) did not receive the intervention and, of those randomised to...
conservative management, 2/15 (13%) received a VAS. There were 12 live births in each arm [12/16 (75%) for VAS vs. 12/15 (80%) for conservative management]. Eight out of 16 (50%) of the babies randomised to VAS survived to 28 days compared with 4/15 (27%) of those randomised to conservative management, giving an ITT analysis relative risk (RR) of 1.88 [95% confidence interval (CI) 0.71 to 4.96] in the direction of benefit with VAS. One baby in each arm died after 28 days giving a RR of 2.19 (95% CI 0.69 to 6.94) at 1 year, again in the direction of benefit with VAS but not excluding harm. Of those babies who survived to 1 year, only two had no evidence of renal impairment (VAS arm), with four in the VAS arm and two in the conservative arm requiring medical management. One baby in the conservative arm had end-stage renal failure at 1 year.

A total of 45 women were entered onto the registry of whom the majority (78%) had conservative management. Those women who entered the study registry and had conservative management were more likely to have a normal liquor volume at diagnosis (greater than the fifth centile) than those receiving VAS (p = 0.07) or those randomised (p = 0.05). There was also a higher proportion with gestational age at diagnosis of ≥ 24 weeks among these women than among those randomised (p = 0.003). These variables were strongly associated with improved survival to 28 days in a multivariable logistic regression analysis.

Over the period of recruitment 68 TOPs for LUTO were notified to the trial office.

Results of the Bayesian analysis
In total, 52 experts provided information on their beliefs about change in perinatal mortality as a result of intrauterine VAS. The elicited opinions combined over all experts gave a prior odds ratio (OR) of 1.22 [95% credible interval (Crl) 0.52 to 2.92] for survival to 28 days with VAS, which, when compared with the trial results in a Bayesian analysis, yielded a RR of 1.31 (95% Crl 0.84 to 2.18), slightly increasing the average and focusing the range of values that can be considered as likely estimates of effect. The possibility that VAS may have a harmful effect could not be ruled out. Combining the trial data and the elicited priors gave a probability of 25% that VAS had a large clinically important effect (a relative increase in survival of 55% or more).

The analysis of survival to 1 year showed VAS to have an effect in the direction of harm [hazard ratio (HR) > 1 favours treatment] from randomisation to birth (36.5 weeks) (HR 0.90, 95% Crl 0.25 to 3.04) and in the direction of benefit between birth and 1 year (HR 1.75, 95% Crl 0.51 to 6.84).

Results of the health economic analysis
The use of VAS was more expensive. In the ITT analysis insertion of VAS incurred an additional cost of approximately £15,500 per survivor at 1 year. The additional cost of VAS per disability-free survival at the end of 1 year was much higher, at about £43,900.

Results of the patient acceptability study
The acceptability study found that various factors were influential to women when they were deciding whether to take part in research during pregnancy. Positive influences were visualisation of the fetus during ultrasound scanning and perceiving a benefit from the trial, but women were similarly motivated to participate for altruistic reasons. Fear of VAS and the perceived severity of LUTO in the baby tended to result in non-participation in the study. The need for more detailed information about the condition and its implications during pregnancy and following delivery was a further important finding of this research.

Results of the epidemiological study
There were 284 LUTO cases among 851,419 total births in the West Midlands region from 1 January 1995 to 31 December 1997, giving an incidence of 3.34 (95% CI 2.95 to 3.72) per 10,000 total births, which was observed to be stable over time. The incidence of LUTO was significantly higher in black and minority ethnic groups and was associated with area-based deprivation measures (p < 0.01). Of the 284 cases, 221 (77.8%) were isolated and the remainder were associated with other structural or chromosomal anomalies. There were 211 (74.3%) cases of isolated, non-female, singleton foetuses, which would fit the
trial eligibility criteria, but only 46.9% (99/211) had been diagnosed prenatally and thus would be suitable for inclusion in the trial.

**Conclusions**

The PLUTO trial stopped early because of poor recruitment. The conclusions that can be drawn from the study concerning the relative effectiveness of VAS are uncertain as they are based on only 31 participants. Survival to 28 days and 1 year appeared to be higher with VAS but the uncertainty in the direction and magnitude of the effect is high and it is not possible to conclude benefit. However, prognosis in both arms (conservative and VAS) at 12 months is poor, with only two babies overall surviving to 1 year of age with no renal impairment. This finding reinforces the natural pathogenesis of this fetal disease as one of severe and significant mortality and morbidity independent of treatment and suggests that, even if perinatal survival is increased, VAS may not have a long-term benefit. A high number of women did not receive the treatment allocated because of clinician choice or a changing clinical picture. Relatively few women were willing to consider randomisation and opted instead for either entry onto the registry or TOP.

The analysis of expert opinion concerning the value of VAS for 28-day mortality showed that experts have uncertainty of its value. Combining expert opinion with the trial data suggests that the data should persuade experts to hold a more positive view, but not to rule out the possibility of harm.

Data from the whole cohort (RCT and registry) demonstrated that normal liquor volume (greater than the fifth centile) and age at diagnosis of ≥ 24 weeks are associated with increased probability of survival at 28 days in fetuses with a confirmed diagnosis of LUTO.

Patients in the VAS arm accrued more expenses than those in the conservative management arm, mainly because of costs associated with additional surgery and intensive care. The observed increase in survival at 28 days and 1 year, if real, needs to be considered in relation to this increase in cost. The cost-effectiveness analysis suggested that these costs are likely to be very high for the benefits observed up to 1 year. Long-term follow-up data are needed to complete this analysis.

**Why was it difficult to recruit?**

Influences on women’s participation in the RCT were perceived benefit, altruism and to increase scientific knowledge and understanding. Fear of the shunting procedure, personal faith and perceived extent of the condition were reasons suggested as influential in non-participation in the RCT. The ability to have open, detailed and ongoing communication with a health professional dedicated to the study appeared to be a positive influence on participation in this research. The finding that the expert clinicians who took part in the Bayesian elicitation exercise were quite pessimistic suggests that many clinicians may not have referred patients for inclusion in the PLUTO trial because of preconceived opinions that the intervention was not beneficial. The epidemiological study also noted the incidence of LUTO to be lower than previously reported, with a high percentage of cases not detected antenatally and thus unable to be included in the trial. Parental choice of TOP was not insignificant in this cohort (and indeed in those pregnancies with apparently isolated LUTO). Bureaucratic barriers and delays were also experienced, related to governance, insurance and approvals for an international trial in this field.

**Implications for health care**

The results of the RCT suggest that VAS may improve overall perinatal survival compared with conservative management but that the long-term prognosis for these babies into infant life is poor (with high rates of mortality and morbidity). Although VAS may increase survival compare with conservative management, it is
unlikely to be a cost-effective option. Parents should be counselled about the risks of pregnancy loss with or without VAS insertion. The National Institute for Health and Care Excellence (NICE) interventional procedures guidance (IPG 202) should be updated to reflect this new evidence.

Women (and their families) faced with a difficult diagnosis in pregnancy should be appropriately counselled (by professionals from different disciplines/specialties) and supported and, when considering entry into research studies, the recruitment process should ideally use an individualised approach with a dedicated research midwife/clinician.

**Recommendations for future research**

Ideally, a larger RCT would be performed but it is unlikely that this would be funded or delivered. Thus, it is imperative that the babies recruited into the PLUTO trial are prospectively followed up throughout childhood to determine the effects of VAS on outcomes such as renal function, incontinence, cognitive development and quality of life. Further research should look at ways to overcome the barriers to recruitment identified within this study, namely the methodology of RCTs in rare diseases (especially relating to pregnancy). Higher education institutions and funders must work hard to resolve the issue of indemnity and sponsorship to allow international collaboration in the research into rare diseases. The factors that appear to influence decision-making with regard to participation in an RCT may be used to tailor future research designs to meet the needs of pregnant women and address the issues of importance to them around this difficult time.

**Trial registration**

This trial is registered as ISRCTN53328556.

**Funding**

Funding for this study was provided by the Health Technology Assessment programme of the National Institute for Health Research.
Criteria for inclusion in the Health Technology Assessment journal

Reports are published in Health Technology Assessment (HTA) if (1) they have resulted from work for the HTA programme, and (2) they are of a sufficiently high scientific quality as assessed by the reviewers and editors.

Reviews in Health Technology Assessment are termed ‘systematic’ when the account of the search appraisal and synthesis methods (to minimise biases and random errors) would, in theory, permit the replication of the review by others.

HTA programme

The HTA programme, part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the effectiveness, costs and broader impact of health technologies for those who use, manage and provide care in the NHS. ‘Health technologies’ are broadly defined as all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care.

The journal is indexed in NHS Evidence via its abstracts included in MEDLINE and its Technology Assessment Reports inform National Institute for Health and Care Excellence (NICE) guidance. HTA research is also an important source of evidence for National Screening Committee (NSC) policy decisions.

For more information about the HTA programme please visit the website: www.hta.ac.uk/

This report

The research reported in this issue of the journal was funded by the HTA programme as project number 07/01/44. The contractual start date was in September 2008. The draft report began editorial review in October 2012 and was accepted for publication in February 2013. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The HTA editors and publisher have tried to ensure the accuracy of the authors’ report and would like to thank the reviewers for their constructive comments on the draft document. However, they do not accept liability for damages or losses arising from material published in this report.

This report presents independent research funded by the National Institute for Health Research (NIHR). The views and opinions expressed by authors in this publication are those of the authors and do not necessarily reflect those of the NHS, the NIHR, NETSCC, the HTA programme or the Department of Health. If there are verbatim quotations included in this publication the views and opinions expressed by the interviewees are those of the interviewees and do not necessarily reflect those of the authors, those of the NHS, the NIHR, NETSCC, the HTA programme or the Department of Health.

© Queen’s Printer and Controller of HMSO 2013. This work was produced by Morris et al. under the terms of a commissioning contract issued by the Secretary of State for Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK.

Published by the NIHR Journals Library (www.journalslibrary.nihr.ac.uk), produced by Prepress Projects Ltd, Perth, Scotland (www.prepress-projects.co.uk).
Editor-in-Chief of Health Technology Assessment and NIHR Journals Library

Professor Tom Walley  Director, NIHR Evaluation, Trials and Studies and Director of the HTA Programme, UK

NIHR Journals Library Editors

Professor Ken Stein  Chair of HTA Editorial Board and Professor of Public Health, University of Exeter Medical School, UK

Professor Andree Le May  Chair of NIHR Journals Library Editorial Group (EME, HS&DR, PGfAR, PHR journals)

Dr Martin Ashton-Key  Consultant in Public Health Medicine/Consultant Advisor, NETSCC, UK

Professor Matthias Beck  Chair in Public Sector Management and Subject Leader (Management Group), Queen's University Management School, Queen's University Belfast, UK

Professor Aileen Clarke  Professor of Health Sciences, Warwick Medical School, University of Warwick, UK

Dr Tessa Crilly  Director, Crystal Blue Consulting Ltd, UK

Dr Peter Davidson  Director of NETSCC, HTA, UK

Ms Tara Lamont  Scientific Advisor, NETSCC, UK

Professor Elaine McColl  Director, Newcastle Clinical Trials Unit, Institute of Health and Society, Newcastle University, UK

Professor William McGuire  Professor of Child Health, Hull York Medical School, University of York, UK

Professor Geoffrey Meads  Honorary Professor, Business School, Winchester University and Medical School, University of Warwick, UK

Professor Jane Norman  Professor of Maternal and Fetal Health, University of Edinburgh, UK

Professor John Powell  Consultant Clinical Adviser, National Institute for Health and Care Excellence (NICE), UK

Professor James Raftery  Professor of Health Technology Assessment, Wessex Institute, Faculty of Medicine, University of Southampton, UK

Dr Rob Riemsma  Reviews Manager, Kleijnen Systematic Reviews Ltd, UK

Professor Helen Roberts  Professorial Research Associate, University College London, UK

Professor Helen Snooks  Professor of Health Services Research, Institute of Life Science, College of Medicine, Swansea University, UK

Please visit the website for a list of members of the NIHR Journals Library Board: www.journalslibrary.nihr.ac.uk/about/editors

Editorial contact: nihredit@southampton.ac.uk